Drugs / P276-00
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01333137 | Aug 2011 → Jul 2012 | breast cancer | Piramal Enterprises Limited | Terminated | No outcome recorded |
| Phase 1 | NCT00547404 | Dec 2008 → Dec 2009 | plasma cell myeloma | Piramal Enterprises Limited | Withdrawn | No outcome recorded |
| Phase 1 | NCT00408018 | Mar 2006 → Aug 2008 | neoplasm | Piramal Enterprises Limited | Terminated | No outcome recorded |
| Phase 1 | NCT00407498 | May 2005 → Mar 2008 | neoplasm | Piramal Enterprises Limited | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT00899054 | Aug 2009 → Jan 2011 | head and neck squamous cell carcinoma | Piramal Enterprises Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT00898287 | May 2009 → Dec 2010 | pancreatic adenocarcinoma | Piramal Enterprises Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT00882063 | Jan 2008 → Nov 2009 | refractory plasma cell neoplasm | Piramal Enterprises Limited | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01903018 | Jul 2012 → Mar 2014 | radiation-induced disorder | Piramal Enterprises Limited | Completed | No outcome recorded |
| Phase 2 | NCT00843050 | Nov 2009 → Feb 2011 | mantle cell lymphoma | Piramal Enterprises Limited | Terminated | No outcome recorded |
| Phase 2 | NCT00835419 | May 2009 → Apr 2011 | melanoma | Piramal Enterprises Limited | Completed | No outcome recorded |
| Phase 2 | NCT00824343 | Sep 2008 → Apr 2011 | head and neck squamous cell carcinoma | Piramal Enterprises Limited | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P276-00 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00408018 ↗ |
| Action | Inhibit | “P276-00 is specific Cdk4-D1 and Cdk1-B inhibitor.” NCT00407498 ↗ |
| Modality | Small molecule | “P276-00 is a novel potent small molecule flavone derived Cyclin dependent kinase (Cdk) Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor.” NCT00835419 ↗ |
| Route | Intravenous | “IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles” NCT00547404 ↗ |
| Target | CDK1 | “P276-00 is specific Cdk4-D1 and Cdk1-B inhibitor.” NCT00407498 ↗ |
| Target | CDK4 | “P276-00 is specific Cdk4-D1 and Cdk1-B inhibitor.” NCT00407498 ↗ |